Researchers at the Icahn School of Medicine at Mount Sinai have identified a previously hidden druggable site in a cancer-related protein that could open the door toward the development of a new ...

• Establishing pharmacologically relevant exposure levels and engagement are two key steps in target validation. • There is a need for better biomarkers to objectively measure biological states and ...

Accelerating Drug Discovery with AI and Next-Generation Automation The pharmaceutical industry is currently witnessi ...

AI has attracted enormous investment across drug discovery, but major questions still remain around validation, ...

Harbour BioMed and BioMap will build a globally leading AI-driven complex biologics AIDD infrastructure platform for ...

A new study identified protein targets and drug candidates, including opportunities to repurpose existing drugs. Six key ...

Zhongyao Ma, PhD, holds a bachelor’s degree in biology from Shanghai Jiao Tong University and a PhD in genetics and developmental biology from the University of Georgia, U.S. His research focused on ...

No approved drug, clinical-stage asset, or competing research program targets the mechanisms that Liquid's Emerge platform identifies.

Smart multi-target drugs are reshaping modern therapeutics by addressing the complex, interconnected pathways that drive diseases like Alzheimer’s, cancer, and major depressive disorder. Advances in ...

Ibogaine’s unconventional “matrix pharmacology” may underlie both its therapeutic promise and unpredictable cardiac risks.